Story
CarMax Stock Surges on Q2 Earnings and Revenue Beat

Summary
CarMax (KMX) shares rallied after the used-car retailer reported second-quarter earnings and revenue that significantly surpassed analyst expectations, driven by strong sales volume and a renewed share buyback plan.
CarMax (NYSE: KMX) shares surged in pre-market trading after the used-car retailer announced fiscal second-quarter results that far surpassed analyst expectations, signaling robust consumer demand and operational strength.
Earnings Beat in Detail
The company reported net income of $1.16 per share for the quarter ending August 31, 2026, easily beating the consensus analyst estimate of $0.68 per share, according to Investing.com. Revenue also significantly outperformed, coming in at $7.88 billion against forecasts of approximately $7.06 billion.
The strong top-line and bottom-line results were supported by impressive operational metrics:
- Total net revenues increased 19.5% year-over-year.
- Combined retail and wholesale unit sales grew 14.7% to 387,735 vehicles.
- Comparable store used unit sales, a key indicator of retail health, rose 13.0%.
- Net earnings per diluted share jumped 81.3% compared to the same period last year.
Management Actions Boost Confidence
AdBolstering investor sentiment, CarMax announced it will resume its share repurchase program during the third fiscal quarter. This move is typically interpreted by markets as a sign of management's confidence in the company's financial health and future prospects.
The company also reaffirmed it is on track to achieve its targeted $200 million in selling, general, and administrative (SG&A) expense reductions by the end of fiscal 2027, underscoring a commitment to cost discipline alongside growth.
Market Reaction and Context
The stock's sharp upward move was a company-specific event, standing in contrast to a largely flat broader market. The scale of the earnings beat surprised market participants, exceeding both cautious analyst positioning ahead of the report and the potential stock move that options markets had priced in.
For investors, the strong results provide fresh evidence that CarMax's turnaround efforts, focused on cost efficiency and sales volume growth, are gaining significant traction.
Read next
More on Stocks
ClearPoint Neuro Stock Plummets 24% on uniQure's Huntington's Trial Setback
Shares of ClearPoint Neuro fell sharply after its partner, uniQure, announced that its experimental gene therapy for Huntington's disease failed to meet its primary goal in a clinical trial, raising concerns about future revenue for ClearPoint's delivery technology.

Webull to Launch No-Code AI Tool for Trade Preparation via Claude, Perplexity
The online brokerage is expanding its cloud-based AI integration, allowing eligible U.S. users to research markets and prepare trades using natural language on platforms like Claude and Perplexity, without any software installation.

Iovance Biotherapeutics Raises Revenue Forecast on Strong Amtagvi Demand, Shares Surge
The biotech company boosted its full-year 2026 revenue guidance by approximately 15% at the midpoint, citing accelerating demand for its cancer therapies Amtagvi and Proleukin.

J.P. Morgan Upgrades Bureau Veritas to Overweight on Growth and M&A Outlook
J.P. Morgan raised its rating on the inspection and certification firm to “Overweight,” citing an expected recovery in organic growth driven by data centers and an increased capacity for acquisitions.